Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven M Horwitz

Showing results (91-100 of 209) with videos related to

Pageof 21
Sort By:
Blood|March 7, 2018
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomasMichelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 14, 2020
Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort StudyFrederick Lansigan, Steven M Horwitz, Lauren C Pinter-Brown, et al.
American Journal of Hematology|August 11, 2018
Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 studySusan O'Brien, Manish Patel, Brad S Kahl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2026
Duvelisib Induces Deep Responses in PTCL: Final Results of the Phase 2 PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell LymphomaNeha Mehta-Shah, Pier Luigi Zinzani, Eric D Jacobsen, et al.
Blood|March 8, 2012
Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphomaSteven M Horwitz, Youn H Kim, Francine Foss, et al.
British Journal of Haematology|May 22, 2023
Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphomaRobert Stuver, Steven M Horwitz, Ranjana H Advani, et al.
Biorxiv : the Preprint Server for Biology|April 15, 2024
Onco-Circuit Addiction and Onco-Nutrient mTORC1 Signaling Vulnerability in a Model of Aggressive T Cell MalignancyXinxin Wang, Andrew E Cornish, Mytrang H Do, et al.
Leukemia & Lymphoma|February 8, 2025
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphomaSteven M Horwitz, Tatyana A Feldman, Jing Christine Ye, et al.
Blood Cancer Journal|November 10, 2020
Targeted genomic analysis of cutaneous T cell lymphomas identifies a subset with aggressive clinicopathological featuresKimon V Argyropoulos, Melissa Pulitzer, Francesco Maura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative ProjectYoun H Kim, Mahkam Tavallaee, Uma Sundram, et al.
Pageof 21

Showing results (91-100 of 209) with videos related to

Sort By:
Pageof 21
Blood|March 7, 2018
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomasMichelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 14, 2020
Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort StudyFrederick Lansigan, Steven M Horwitz, Lauren C Pinter-Brown, et al.
American Journal of Hematology|August 11, 2018
Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 studySusan O'Brien, Manish Patel, Brad S Kahl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2026
Duvelisib Induces Deep Responses in PTCL: Final Results of the Phase 2 PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell LymphomaNeha Mehta-Shah, Pier Luigi Zinzani, Eric D Jacobsen, et al.
Blood|March 8, 2012
Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphomaSteven M Horwitz, Youn H Kim, Francine Foss, et al.
British Journal of Haematology|May 22, 2023
Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphomaRobert Stuver, Steven M Horwitz, Ranjana H Advani, et al.
Biorxiv : the Preprint Server for Biology|April 15, 2024
Onco-Circuit Addiction and Onco-Nutrient mTORC1 Signaling Vulnerability in a Model of Aggressive T Cell MalignancyXinxin Wang, Andrew E Cornish, Mytrang H Do, et al.
Leukemia & Lymphoma|February 8, 2025
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphomaSteven M Horwitz, Tatyana A Feldman, Jing Christine Ye, et al.
Blood Cancer Journal|November 10, 2020
Targeted genomic analysis of cutaneous T cell lymphomas identifies a subset with aggressive clinicopathological featuresKimon V Argyropoulos, Melissa Pulitzer, Francesco Maura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative ProjectYoun H Kim, Mahkam Tavallaee, Uma Sundram, et al.
Pageof 21